Focal Segmental Glomerulosclerosis Medical Services in China

Focal Segmental Glomerulosclerosis (FSGS) is a histopathological pattern of kidney injury characterized by scarring (sclerosis) affecting only some (focal) glomeruli and only portions (segmental) of those affected glomeruli. It is not a single disease but rather a clinicopathologic syndrome with diverse underlying causes—including genetic mutations, viral infections (e.g., HIV), adaptive responses to reduced nephron mass, autoimmune dysregulation, and circulating permeability factors (e.g., soluble urokinase receptor, anti-CD40 antibodies). The pathogenesis involves podocyte injury and depletion, leading to disruption of the glomerular filtration barrier, proteinuria, and progressive glomerular collapse. Primary (idiopathic) FSGS is often mediated by circulating permeability factors that cause podocyte cytoskeletal rearrangement and foot process effacement; secondary forms arise from systemic conditions such as obesity, reflux nephropathy, sickle cell disease, or chronic hypertension. Epidemiologically, FSGS accounts for approximately 15–25% of adult-onset nephrotic syndrome cases in North America and Europe, and its incidence appears to be rising globally—particularly in Black populations, where genetic variants in the APOL1 gene confer markedly increased risk (up to 7–10-fold higher susceptibility). Other key risk factors include male sex, age 18–50 years, obesity (BMI ≥30), HIV infection, heroin use, and prior renal insults (e.g., reflux, obstruction). Clinically, patients commonly present with heavy proteinuria (>3.5 g/day), hypoalbuminemia, edema, and hyperlipidemia—though up to 30% may have subnephrotic proteinuria or even normal renal function at diagnosis. Hypertension and impaired GFR often develop as disease progresses. Without intervention, ~50% of untreated primary FSGS cases progress to end-stage kidney disease (ESKD) within 5–10 years. Quality of life is significantly impacted: persistent edema and fatigue limit physical activity; recurrent infections (due to immunosuppression and loss of immunoglobulins in urine) increase hospitalizations; dietary restrictions (low-sodium, low-protein), medication side effects (e.g., corticosteroid-induced weight gain, mood changes, osteoporosis), and financial burden of long-term care contribute to anxiety, depression, and social isolation. Children and young adults face particular psychosocial challenges related to school/work absenteeism, body image concerns, and fertility implications. Early diagnosis via kidney biopsy—and differentiation between primary, genetic, and secondary forms—is critical for guiding targeted therapy and prognostication.

Focal Segmental Glomerulosclerosis (FSGS) is a histopathologic pattern of kidney injury characterized by segmental scarring (sclerosis) affecting some, but not all, glomeruli. It is not a single disease but rather a clinicopathologic syndrome with diverse etiologies spanning primary (idiopathic), genetic, viral, drug-induced, adaptive, and secondary forms. Understanding its causes and risk factors is essential for accurate diagnosis, prognostication, and targeted therapy.

Common causes include primary (idiopathic) FSGS, which accounts for approximately 70–80% of cases in adults presenting with nephrotic syndrome. This form is believed to be mediated by circulating permeability factors—most notably soluble urokinase plasminogen activator receptor (suPAR) and anti-CD40 antibodies—that disrupt podocyte integrity and slit diaphragm function, leading to proteinuria and progressive glomerular injury. Secondary FSGS arises from adaptive structural changes in response to reduced nephron mass or hyperfiltration stress; common triggers include obesity-related glomerulopathy, reflux nephropathy, unilateral renal agenesis, extensive renal ablation (e.g., after partial nephrectomy or infarction), and chronic hypertension. Viral-associated FSGS is well documented in HIV infection (HIV-associated nephropathy, or HIVAN), where direct viral infection of podocytes and tubular epithelial cells drives collapsing variant FSGS. Parvovirus B19 and cytomegalovirus have also been implicated in rare cases.

Key risk factors encompass demographic, clinical, and physiological variables. African ancestry confers significantly increased susceptibility—individuals of African descent are 3–5 times more likely to develop FSGS and experience faster progression to end-stage kidney disease (ESKD), partly attributable to high-risk APOL1 gene variants. Male sex, younger age at onset (particularly <25 years), and higher baseline proteinuria (>8 g/day) strongly predict poor renal outcomes. Obesity (BMI ≥30 kg/m²) independently increases risk through hemodynamic stress, adipokine-mediated inflammation, and activation of the renin-angiotensin-aldosterone system (RAAS). Uncontrolled hypertension exacerbates glomerular capillary pressure and accelerates sclerosis. Recurrent or persistent nephrotic syndrome post-transplant—especially in patients with primary FSGS—carries a 30–50% recurrence risk, often within hours to days post-transplant, reflecting the persistence of pathogenic circulating factors.

Genetic factors play a pivotal role, particularly in pediatric-onset and familial FSGS. Over 50 monogenic causes have been identified, most involving podocyte-expressed proteins critical for cytoskeletal architecture, slit diaphragm signaling, or mitochondrial function. Common mutations occur in NPHS1 (nephrin), NPHS2 (podocin), TRPC6, ACTN4 (alpha-actinin-4), INF2, and WT1. Autosomal recessive inheritance predominates in early childhood cases, while autosomal dominant patterns are frequent in adolescent and adult-onset familial disease. The APOL1 G1 and G2 risk alleles—found almost exclusively in individuals with recent West African ancestry—confer markedly increased risk for FSGS, HIVAN, and hypertension-attributed CKD; having two risk alleles increases lifetime risk of FSGS by ~7–10-fold. These variants likely confer evolutionary advantage against Trypanosoma brucei infection but predispose to podocyte injury under inflammatory or infectious stress.

Environmental factors contribute both directly and indirectly. Prolonged exposure to certain toxins—including heroin, pamidronate, and interferon-alpha—has been associated with FSGS development. Viral exposures (HIV, parvovirus, SARS-CoV-2) may trigger immune dysregulation or direct podocyte injury. Chronic NSAID use, especially in volume-depleted states, can promote intraglomerular hypertension and podocyte stress. Socioeconomic determinants—including limited access to timely nephrology care, delayed diagnosis, food insecurity, and environmental pollution—exacerbate disparities in incidence and progression, particularly among marginalized populations. Additionally, dietary factors such as high-sodium intake and excessive animal protein consumption may amplify hyperfiltration and glomerular injury in susceptible individuals. In summary, FSGS emerges from complex interactions among genetic susceptibility, immune dysregulation, hemodynamic stress, environmental exposures, and systemic comorbidities—necessitating a comprehensive, individualized approach to evaluation and management in nephrology practice.

Focal Segmental Glomerulosclerosis (FSGS) is a histopathological pattern of kidney injury characterized by segmental scarring (sclerosis) affecting some, but not all, glomeruli (hence 'focal') and involving only portions of affected glomeruli (hence 'segmental'). It represents a common cause of nephrotic syndrome in adults and children and may arise from genetic, adaptive, viral (e.g., HIV), drug-induced, or idiopathic mechanisms. Clinically, FSGS often presents insidiously, with symptoms reflecting progressive podocyte injury, glomerular barrier dysfunction, and declining glomerular filtration rate (GFR).

Early symptoms are frequently subtle or entirely absent. Patients may report mild, non-specific fatigue, decreased exercise tolerance, or intermittent periorbital or lower-limb swelling noticed upon waking or after prolonged standing—often dismissed as benign edema. Subtle weight gain due to fluid retention may be the first objective sign, though it typically lacks acute onset. Laboratory abnormalities often precede overt clinical manifestations: persistent proteinuria (>300 mg/day on spot urine albumin-to-creatinine ratio or >1 g/24 h) is the earliest and most consistent finding, frequently detected incidentally during routine urinalysis or pre-employment screening. Microscopic hematuria (dysmorphic red blood cells, RBC casts) may be present in up to 30% of cases but is neither sensitive nor specific. Serum creatinine may remain normal initially, though estimated GFR (eGFR) may show a slow, subclinical decline over months to years—particularly in secondary or adaptive forms (e.g., obesity-related or post-nephrectomy FSGS). Hypertension may emerge early in patients with underlying cardiovascular risk factors or reduced renal mass, even before significant proteinuria develops.

Typical symptoms reflect established nephrotic syndrome: heavy proteinuria (>3.5 g/24 h), hypoalbuminemia (<3.0 g/dL), peripheral edema (especially pretibial and periorbital), and hyperlipidemia. Edema is often asymmetric, progressive, and refractory to diuretics; it may culminate in anasarca or pleural effusions. Patients commonly describe abdominal fullness or bloating due to ascites, dyspnea on exertion secondary to pulmonary congestion or pleural effusion, and frothy urine—a hallmark visual clue of severe proteinuria. Fatigue and malaise intensify due to hypoalbuminemia, chronic inflammation, and potential vitamin D deficiency. Weight gain exceeding 5–10 kg over weeks is typical. In children, growth retardation and delayed puberty may occur with prolonged untreated disease.

Accompanying symptoms include signs of hypercoagulability (e.g., unexplained deep vein thrombosis, pulmonary embolism, or renal vein thrombosis), which stem from urinary losses of antithrombin III, protein S, and plasminogen. Patients may report recurrent infections—particularly spontaneous bacterial peritonitis or cellulitis—due to loss of immunoglobulins and complement factors in urine. Hypothyroidism (from urinary thyroxine-binding globulin loss) may manifest as cold intolerance, constipation, or bradycardia. Vitamin D deficiency contributes to bone pain or proximal muscle weakness. Some patients develop pruritus related to uremic toxin accumulation or cholestasis-like lipid abnormalities. In HIV-associated FSGS, constitutional symptoms such as fever, night sweats, or weight loss may coexist with renal findings.

Complications arise from both nephrotic syndrome and progressive chronic kidney disease (CKD). Acute kidney injury (AKI) can occur secondary to intravascular volume depletion (from aggressive diuresis or gastrointestinal losses), renal vein thrombosis, or interstitial nephritis. Accelerated hypertension and left ventricular hypertrophy increase cardiovascular morbidity and mortality. CKD progression is variable: idiopathic FSGS carries a high risk of end-stage kidney disease (ESKD), with ~50% progressing to dialysis or transplantation within 5–10 years without remission. Recurrence post-transplant occurs in 30–50% of primary FSGS cases, often within hours to days, leading to rapid graft loss. Other complications include acute tubular necrosis from contrast exposure or NSAID use, steroid-induced diabetes or osteoporosis during treatment, and increased susceptibility to encapsulated organisms (e.g., Streptococcus pneumoniae) due to functional asplenia-like immune dysfunction.

Diagnosis relies on integration of clinical, laboratory, and histopathological data. Urinalysis reveals nephrotic-range proteinuria, lipiduria (oval fat bodies, fatty casts), and occasional hematuria. Serum studies show hypoalbuminemia, elevated total cholesterol and LDL, low serum IgG and antithrombin III, and often elevated serum creatinine with reduced eGFR. Renal ultrasound typically shows normal or slightly increased kidney size with preserved corticomedullary differentiation early on; later stages may demonstrate cortical thinning and increased echogenicity. Definitive diagnosis requires percutaneous kidney biopsy with light microscopy (showing segmental sclerosis and hyalinosis), immunofluorescence (typically negative for immune deposits—'pauci-immune'), and electron microscopy (revealing diffuse podocyte foot process effacement). Genetic testing (e.g., NPHS1, NPHS2, TRPC6, ACTN4) is indicated in pediatric-onset, familial, or steroid-resistant cases. Circulating permeability factor assays (e.g., soluble urokinase receptor [suPAR] levels) remain investigational but may support primary FSGS diagnosis in select contexts.

Differential diagnosis must exclude other causes of nephrotic syndrome and glomerular sclerosis. Minimal change disease (MCD) shares clinical features but lacks sclerosis on biopsy and shows complete foot process effacement without structural damage; it responds rapidly to corticosteroids. Membranous nephropathy demonstrates subepithelial immune complex deposits on immunofluorescence and electron microscopy, with anti-PLA2R antibodies in ~70% of cases. Diabetic nephropathy exhibits global glomerulosclerosis, Kimmelstiel-Wilson nodules, and arteriolar hyalinosis—typically in patients with long-standing diabetes and retinopathy. Amyloidosis shows Congo red–positive apple-green birefringence and characteristic fibrillar deposits on electron microscopy. HIV-associated nephropathy (HIVAN) displays collapsing variant FSGS with microcystic tubular dilation and prominent tubulointerstitial inflammation. Secondary FSGS (e.g., adaptive forms) must be distinguished from primary FSGS by careful assessment of renal mass reduction (e.g., solitary kidney, reflux nephropathy), obesity (BMI ≥30), or viral serologies. Finally, Alport syndrome and thin basement membrane nephropathy may mimic early FSGS clinically but lack sclerosis and show characteristic basement membrane abnormalities on electron microscopy.

Focal Segmental Glomerulosclerosis (FSGS) is a histopathological pattern of kidney injury characterized by segmental scarring (sclerosis) affecting some, but not all, glomeruli. It represents a leading cause of nephrotic syndrome in adults and children and may progress to end-stage kidney disease (ESKD) if inadequately controlled. Management requires a multidisciplinary, individualized approach centered on reducing proteinuria, preserving glomerular filtration rate (GFR), mitigating cardiovascular risk, and addressing underlying etiologies—including primary (idiopathic), genetic, viral (e.g., HIV-associated), adaptive (e.g., obesity-related or post-renal ablation), and secondary forms (e.g., drug-induced or autoimmune-associated). Treatment strategies are stratified according to clinical presentation, histologic subtype, estimated GFR, proteinuria severity, and response to prior therapies.

Conservative treatment forms the cornerstone of FSGS management and must be initiated at diagnosis, regardless of pharmacologic intervention. This includes strict blood pressure control targeting <130/80 mmHg using renin-angiotensin-aldosterone system (RAAS) blockade—typically angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs)—which reduce intraglomerular hypertension and proteinuria independent of antihypertensive effect. Dietary sodium restriction (<2 g/day) enhances RAAS inhibitor efficacy and attenuates edema and hypertension. A moderate-protein diet (0.8–1.0 g/kg/day) is recommended to minimize glomerular hyperfiltration without inducing malnutrition; high-protein diets (>1.3 g/kg/day) are contraindicated. Lipid-lowering therapy with statins is indicated for patients with nephrotic-range proteinuria and dyslipidemia to reduce cardiovascular morbidity. Fluid and weight monitoring, vaccination (especially pneumococcal and influenza), and avoidance of nephrotoxins—including NSAIDs, iodinated contrast, and herbal nephrotoxins (e.g., aristolochic acid)—are essential components of conservative care.

Pharmacotherapy is guided by disease classification and response. For primary (idiopathic) FSGS with nephrotic syndrome and preserved GFR (>60 mL/min/1.73m²), first-line immunosuppression consists of oral corticosteroids: prednisone 1 mg/kg/day (max 80 mg) for 4–6 weeks, followed by alternate-day taper over 4–6 months. Steroid resistance—defined as failure to achieve remission after ≥16 weeks of adequate dosing—warrants escalation to calcineurin inhibitors (CNIs): cyclosporine (3–5 mg/kg/day in two divided doses, targeting trough levels 100–150 ng/mL) or tacrolimus (0.05–0.1 mg/kg/day, trough 5–10 ng/mL), typically combined with low-dose prednisone (0.15 mg/kg every other day). Mycophenolate mofetil (MMF) (1–2 g/day) may serve as steroid-sparing agent or second-line option in CNI-intolerant patients. Emerging biologics—including rituximab (375 mg/m² weekly × 4 or 1 g × 2 doses 2 weeks apart) and abatacept—are under active investigation in refractory cases, particularly those with circulating permeability factors. For genetic or syndromic FSGS (e.g., mutations in NPHS1, NPHS2, TRPC6), immunosuppression is generally ineffective and avoided; management focuses on supportive care and timely renal replacement planning. In HIV-associated FSGS, antiretroviral therapy (ART) remains primary, with adjunctive RAAS inhibition.

Surgical treatment has no direct role in FSGS pathogenesis but becomes relevant in specific contexts. Nephrectomy is rarely indicated—only in rare cases of unilateral massive proteinuria with documented asymmetric disease and preserved contralateral function, which remains controversial and unsupported by robust evidence. More commonly, surgical intervention relates to complications: placement of tunneled dialysis catheters or arteriovenous fistulas for patients progressing to ESKD, or native kidney biopsy (percutaneous ultrasound-guided) for definitive diagnosis and subclassification—critical before initiating immunosuppression. In select patients with recurrent FSGS post-transplant (occurring in ~30–50% of primary FSGS recipients), preemptive plasmapheresis or rituximab may be employed perioperatively, though evidence remains limited.

China offers distinct advantages in FSGS management, rooted in integrated healthcare infrastructure, rapid diagnostic capacity, and innovation in therapeutics. Major tertiary hospitals—such as Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—house specialized glomerular disease centers with standardized biopsy protocols, electron microscopy, and immunofluorescence capabilities enabling precise histologic subtyping within 72 hours. China’s national registry for glomerular diseases facilitates real-world outcome tracking and informs evidence-based guidelines updated annually by the Chinese Society of Nephrology (CSN). Pharmacologically, domestically manufactured biosimilar CNIs and rituximab have significantly improved affordability and access; cost of a 6-month CNI regimen is approximately 30–50% lower than in Western markets. Moreover, China leads in clinical trials of novel agents—including anti-APOL1 therapies (in development for high-risk genetic variants) and targeted complement inhibitors—and hosts >25% of global FSGS interventional studies. Traditional Chinese Medicine (TCM) adjuncts—such as tripterygium glycosides (used cautiously under nephrology supervision)—are integrated into multimodal regimens where evidence supports synergistic antiproteinuric effects, though rigorous RCT data remain limited.

Recovery and long-term prognosis depend heavily on adherence, early intervention, and vigilant monitoring. Patients should undergo quarterly assessments including serum creatinine, estimated GFR, urinary protein-to-creatinine ratio (UPCR), serum albumin, lipid panel, and blood pressure. Sustained remission—defined as UPCR <0.3 g/g for ≥6 months—is associated with markedly slower eGFR decline. Lifestyle counseling must emphasize smoking cessation, structured aerobic exercise (150 min/week), and weight maintenance (BMI 18.5–24.9 kg/m²), especially in adaptive FSGS. Vaccination status should be reviewed annually; annual influenza and pneumococcal vaccines are mandatory. Psychosocial support—including access to certified renal dietitians and mental health professionals—is integral, given the chronic burden of nephrotic syndrome and immunosuppression. Women of childbearing potential require preconception counseling: ACEi/ARBs and CNIs are teratogenic and must be discontinued ≥3 months prior to conception; pregnancy is considered high-risk and necessitates co-management by nephrology and maternal-fetal medicine. Finally, patients with progressive eGFR decline (<45 mL/min/1.73m²) should be referred early to transplant evaluation, as preemptive transplantation confers superior survival versus dialysis initiation. With comprehensive, protocol-driven care, up to 60% of steroid-sensitive FSGS patients achieve sustained remission, and median time to ESKD exceeds 10 years in responsive cohorts.